Alpha-Lipoic Acid
acidum thiocticum (thioctic acid)
A mitochondrial antioxidant best known for diabetic nerve symptoms, but recent rigorous trials temper the hype.
Evidence tier
Mixed
Research weight
Citations
19 verified / 19
Classification
Heart & Metabolic
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Alpha-Lipoic Acid?
Alpha-Lipoic Acid (acidum thiocticum (thioctic acid)) is a heart and metabolic supplement used for may modestly reduce symptoms of diabetic peripheral neuropathy (burning, tingling, numbness); historically the strongest signal came from short-term intravenous 600 mg, while recent high-quality oral trials show little clinical benefit at 6 months.. NutriDex grades the human evidence as Mixed. Alpha-lipoic acid (ALA, thioctic acid) is a sulfur-containing compound made in the body and used as a dietary supplement and, in some countries, a prescription drug for diabetic neuropathy. Its main rationale is antioxidant and mitochondrial activity, and its best-studied use is symptomatic diabetic peripheral neuropathy. Earlier work suggested short-term intravenous ALA improved neuropathic symptoms, but a 2024 Cochrane review of oral ALA found it probably has little or no effect on neuropathy symptoms or nerve impairment at six months (moderate-certainty evidence). For metabolic outcomes, meta-analyses show real but small reductions in weight, BMI, fasting glucose, and HbA1c that authors judged not clinically important. Overall the evidence is genuinely mixed: a plausible mechanism and consistent small effects, but recent rigorous trials undercut the larger benefits once attributed to it. It is generally well tolerated, with most concern around hypoglycemia risk and rare hypersensitivity.
Purported Benefits
✓May modestly reduce symptoms of diabetic peripheral neuropathy (burning, tingling, numbness); historically the strongest signal came from short-term intravenous 600 mg, while recent high-quality oral trials show little clinical benefit at 6 months.
✓Produces small, statistically significant reductions in body weight and BMI in pooled trials (roughly 0.7-2.3 kg), but the magnitude is too small to be clinically meaningful on its own.
✓Slightly lowers fasting glucose and HbA1c in type 2 diabetes, though the changes fall below the threshold considered clinically important.
✓Acts as a regenerable antioxidant and metal chelator and regenerates other antioxidants (vitamins C and E, glutathione); broader claims for cognition, energy, and 'detox' are largely unproven in humans.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Reduced diabetic peripheral neuropathy symptomsShort-term IV and older oral trials showed symptom relief, but 2024 Cochrane found oral ALA has little/no effect at 6 months (moderate certainty). | Mixed | ↔ mixed · small | 5 |
| Reduced body weight / BMIPooled RCTs show significant but small weight loss (~1.3-2.3 kg) judged not clinically meaningful alone. | Moderate | ↑ benefit · small | 2 |
| Lower fasting glucose / HbA1cDose-response meta-analysis shows tiny reductions (~0.17% HbA1c per 500 mg) below clinical importance; some analyses find no change. | Mixed | ↑ benefit · negligible | 3 |
| Lower blood pressureGRADE-assessed 11-RCT meta-analysis found ~5.5 mmHg SBP and ~3.4 mmHg DBP reductions vs control. | Moderate | ↑ benefit · small | 1 |
| Reduced inflammatory markers (CRP, IL-6, TNF-alpha)20-RCT meta-analysis shows significant reductions, mainly when baseline CRP is elevated and duration exceeds 8 weeks. | Moderate | ↑ benefit · small | 2 |
| Insulin autoimmune syndrome (hypoglycemia)EFSA and a case report link oral ALA to rare autoimmune hypoglycemia; basis for a 0.6 mg/kg/day upper safe intake. | Preliminary | ⚠ risk | 2 |
Dosing & Compounds
Typical Dose
Oral: 300-600 mg/day (commonly 600 mg, often divided and taken on an empty stomach); clinical neuropathy studies have used up to 1,800 mg/day orally and 600 mg/day intravenously for ~3 weeks.
Active Compounds
Safety & Cautions
Generally well tolerated; the most common side effects are mild gastrointestinal upset (nausea, abdominal pain), headache, and skin rash, and rare allergic/hypersensitivity reactions including insulin autoimmune syndrome (autoimmune hypoglycemia), reported mainly in people with certain HLA genotypes and more often in East Asian populations. Because ALA can lower blood glucose, it may add to the effect of insulin or other antidiabetic drugs and cause hypoglycemia, so glucose should be monitored and medication doses may need adjustment. It may also lower thyroid hormone levels and theoretically interfere with thyroid medication, and it can chelate metals, so spacing from mineral supplements is reasonable. Avoid or use only under medical supervision in pregnancy and breastfeeding (insufficient safety data), in children, in people with thiamine deficiency or heavy alcohol use (deficiency should be corrected first), and in anyone with a prior reaction to ALA. Discuss with a clinician before use if you have diabetes, thyroid disease, or take glucose-lowering, thyroid, or chemotherapy agents; ALA is a supplement, not a substitute for prescribed neuropathy or diabetes treatment. Educational only — always check with your doctor or pharmacist before combining Alpha-Lipoic Acid with any medicine.
Alpha-Lipoic Acid drug interactions
Known or theoretical interactions between Alpha-Lipoic Acid and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Alpha-Lipoic Acid with any medicine.
Monitor
Insulin & oral antidiabetics
May lower blood glucose and add to diabetes medications, raising hypoglycemia risk.
Improves insulin-mediated glucose uptake, adding to glucose-lowering drugs. MSKCC — Alpha-Lipoic Acid
Key Studies ★ 19 studies
Cochrane systematic review / meta-analysis
816 (3 RCTs)
✓ Full text
2024 Cochrane review found oral alpha-lipoic acid probably has little or no effect on diabetic neuropathy symptoms (Total Symptom Score) or nerve impairment at 6 months versus placebo, with moderate-certainty evidence.
Systematic review / meta-analysis
1,077 (6 RCTs)
✓ Full text
2023 systematic review/meta-analysis of ALA for diabetic neuropathic pain reported short-term symptom reductions but concluded there is no solid evidence supporting ALA as a stand-alone therapy and no clearly superior dose or route.
meta-analysis
674 (11 RCTs)
✓ PubMed
A 2023 GRADE-assessed dose-response meta-analysis found alpha-lipoic acid supplementation significantly lowered systolic blood pressure (WMD -5.46 mmHg) and diastolic blood pressure (about -3.4 mmHg) in adults versus control.
meta-analysis
7 RCTs
✓ PubMed
A 2023 systematic review and meta-analysis in women with PCOS found alpha-lipoic acid significantly reduced fasting blood sugar (SMD -0.60; moderate certainty) and HOMA-IR (SMD -2.03; low certainty), but did not significantly change BMI, lipids, sex hormones, or oxidative stress markers.
Systematic review
Canadian J Diabetes 2024
✓ PubMed
Network meta-analysis of 11 studies found 8/11 (73%) reported significant benefit of ALA vs placebo, with Total Symptom Score for ALA 600 mg/day about 1.05 points lower than placebo.
Meta-analysis
Frontiers Cardiovasc Med 2023
✓ Full text
GRADE-assessed dose-response meta-analysis of 11 RCTs (674 patients) found ALA supplementation reduced SBP by 5.46 mmHg (95% CI -9.27 to -1.65) and DBP by 3.36 mmHg (95% CI -4.99 to -1.74).
Meta-analysis
CKD meta-analysis 2024
✓ PubMed
Meta-analysis of RCTs evaluated ALA's effects on inflammatory, lipid, and hematological markers and anthropometric indices in patients with chronic kidney disease.
Meta-analysis
Baicus 2023 (oral ALA polyneuropathy meta-analysis)
✓ PubMed
Systematic review/meta-analysis of RCTs of oral ALA in diabetic polyneuropathy. ALA significantly reduced neuropathic symptoms (pooled Total Symptom Score) vs placebo, but the authors judged the effect size to be of modest/uncertain clinical relevance and quality of evidence limited, contrasting with stronger short-term effects seen with IV administration.
meta-analysis
Dose-response RCTs (to Nov 2020)
✓ PubMed
An updated dose- and duration-response meta-analysis concluded alpha-lipoic acid (300-1200 mg/day, 2-16 weeks) reduced total cholesterol and LDL-cholesterol in a dose- and duration-dependent manner that varied by participants' health status.
Meta-analysis
Jibril 2022 (type 2 diabetes dose-response meta-analysis)
✓ PubMed
Dose-response meta-analysis of RCTs in type 2 diabetes. Oral ALA significantly lowered fasting blood glucose (WMD approximately -8 to -10 mg/dL) and HbA1c, with an apparent dose-response relationship up to ~600 mg/day; effects on insulin/HOMA-IR were less consistent. Generally well tolerated.
guideline
EFSA scientific opinion
✓ Full text
A 2021 EFSA Panel opinion concluded that oral alpha-lipoic acid can trigger insulin autoimmune syndrome (autoimmune hypoglycaemia), deriving an upper safe intake of 0.6 mg/kg body weight/day (about 42 mg/day for a 70 kg adult) for ALA added to foods.
Dose-response meta-analysis of RCTs
1,035 (16 RCTs)
✓ Full text
In type 2 diabetes, each 500 mg/day of oral ALA lowered HbA1c by ~0.17% and fasting glucose by ~6 mg/dL, but authors concluded the cardiometabolic effects were statistically significant yet not clinically important.
Meta-analysis of RCTs
~12 RCTs
✓ PubMed
Pooled placebo-controlled trials found ALA supplementation significantly reduced body weight (about 1.3 kg) and BMI, describing a small but significant short-term weight-loss effect.
Dose-response meta-analysis of RCTs
Dose-response (18/21 studies)
✓ PubMed
An updated dose-response meta-analysis reported ALA significantly reduced body weight (WMD -2.29 kg) and BMI (WMD -0.49 kg/m2) versus placebo across randomized trials.
meta-analysis
20 RCTs
✓ PubMed
An updated dose-response meta-analysis reported alpha-lipoic acid significantly reduced CRP (WMD -0.69 mg/L), IL-6 (-1.83 pg/mL), and TNF-alpha (-0.45 pg/mL) in adults, with CRP reductions seen mainly when baseline CRP exceeded 3 mg/L and trial duration was over 8 weeks.
meta-analysis
18 RCTs
✓ PubMed
In patients with metabolic syndrome and related disorders, alpha-lipoic acid supplementation significantly decreased C-reactive protein, IL-6, and TNF-alpha concentrations versus control.
meta-analysis
1,016 (28 RCTs)
✓ PubMed
An updated dose-response meta-analysis in adults found alpha-lipoic acid supplementation significantly lowered fasting insulin (WMD -0.64) and HOMA-IR (WMD -0.48), while fasting glucose and HbA1c showed no significant change.
RCT
Ziegler 2006 (SYDNEY 2 trial)
✓ PubMed
Landmark multicenter, double-blind, placebo-controlled RCT (n=181, type 1/2 diabetes). Oral alpha-lipoic acid for 5 weeks reduced Total Symptom Score of distal symmetric polyneuropathy by 51% (600 mg), 48% (1200 mg), and 52% (1800 mg) vs 32% for placebo (all P<0.05). 600 mg once daily gave the best risk-benefit ratio; higher doses added GI adverse events without added efficacy.
case report
Case report (n=1)
✓ Full text
A Diabetes Care case report documented insulin autoimmune syndrome with recurrent hypoglycaemia and high insulin-autoantibody titers in a Caucasian woman taking alpha-lipoic acid, with resolution after discontinuation, illustrating a recognized rare adverse effect.